| Original language | English |
|---|---|
| Pages (from-to) | 117-119 |
| Number of pages | 3 |
| Journal | JACC: Clinical Electrophysiology |
| Volume | 8 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2022 |
Access to Document
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Changes in Lead Parameters and Septal Morphology During Left Ventricular Septal Perforation : Preclinical Insights. / Kawamura, Iwanari; Reddy, Vivek Y.; Koruth, Jacob.
In: JACC: Clinical Electrophysiology, Vol. 8, No. 1, 01.2022, p. 117-119.Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Changes in Lead Parameters and Septal Morphology During Left Ventricular Septal Perforation
T2 - Preclinical Insights
AU - Kawamura, Iwanari
AU - Reddy, Vivek Y.
AU - Koruth, Jacob
N1 - Funding Information: Dr Reddy has served as an unpaid consultant for Abbott; unrelated to this paper, has served as a consultant for and has equity in Ablacon, Acutus Medical, Affera, Apama Medical, Aquaheart, Atacor, Autonomix, Backbeat, BioSig, Circa Scientific, Coria Medical, Dinova-Hangzhou Nuomao Medtech Co, East End Medical, EPD, Epix Therapeutics, EpiEP, Eximo, Fire1, Javelin, Kardium, Keystone Heart, LuxCath, Medlumics, Middlepeak, Nuvera, Sirona Medical, and Valcare; unrelated to this work, has served as a consultant for Axon, Biotronik, Cardiofocus, Cardionomic, CardioNXT/AFTx, EBR, Impulse Dynamics, Medtronic, Philips, Pulse Biosciences, Stimda, and Thermedical; and has equity in Manual Surgical Sciences, Newpace, Surecor, and Vizaramed. Dr Koruth has been a consultant for Vytronus, Abbott, Cardiofocus and Farapulse; has received grant support from Vytronus, Farapulse, Cardiofocus, Luxcath, Affera, and Biosense; and holds stock options in Affera. Dr Kawamura has reported that he has no relationships relevant to the contents of this paper to disclose. The authors would like to acknowledge the assistance of Willam M. Gabrell, BBA, CCDS, and Neil Kotey, BFA, CCDS, for their assistance with this study. Funding Information: Dr Reddy has served as an unpaid consultant for Abbott; unrelated to this paper, has served as a consultant for and has equity in Ablacon, Acutus Medical, Affera, Apama Medical, Aquaheart, Atacor, Autonomix, Backbeat, BioSig, Circa Scientific, Coria Medical, Dinova-Hangzhou Nuomao Medtech Co, East End Medical, EPD, Epix Therapeutics, EpiEP, Eximo, Fire1, Javelin, Kardium, Keystone Heart, LuxCath, Medlumics, Middlepeak, Nuvera, Sirona Medical, and Valcare; unrelated to this work, has served as a consultant for Axon, Biotronik, Cardiofocus, Cardionomic, CardioNXT/AFTx, EBR, Impulse Dynamics, Medtronic, Philips, Pulse Biosciences, Stimda, and Thermedical; and has equity in Manual Surgical Sciences, Newpace, Surecor, and Vizaramed. Dr Koruth has been a consultant for Vytronus, Abbott, Cardiofocus and Farapulse; has received grant support from Vytronus, Farapulse, Cardiofocus, Luxcath, Affera, and Biosense; and holds stock options in Affera. Dr Kawamura has reported that he has no relationships relevant to the contents of this paper to disclose. The authors would like to acknowledge the assistance of Willam M. Gabrell, BBA, CCDS, and Neil Kotey, BFA, CCDS, for their assistance with this study.
PY - 2022/1
Y1 - 2022/1
UR - http://www.scopus.com/inward/record.url?scp=85122526013&partnerID=8YFLogxK
U2 - 10.1016/j.jacep.2021.12.009
DO - 10.1016/j.jacep.2021.12.009
M3 - Letter
C2 - 35057975
AN - SCOPUS:85122526013
SN - 2405-5018
VL - 8
SP - 117
EP - 119
JO - JACC: Clinical Electrophysiology
JF - JACC: Clinical Electrophysiology
IS - 1
ER -